FCR (Fludarabine, Cyclophosphamide, and Rituximab)

FCR is a combination of three therapies used to treat certain blood cancers, like chronic lymphocytic leukemia (CLL). It includes Fludarabine, a chemotherapy drug that kills cancer cells; Cyclophosphamide, another chemotherapy agent that damages cancer cell DNA; and Rituximab, a targeted antibody that recognizes and destroys cancer cells expressing the CD20 protein. Together, these medications work synergistically to reduce or eliminate cancer, often leading to remission. FCR is administered under medical supervision, with careful monitoring for side effects, and has been a standard, effective treatment for suitable patients.